The GMO debate – what does the science say? Are we listening?

Food Evolution, a new documentary by Academy Award™-nominated director Scott Hamilton Kennedy, was screened in Toronto and Waterloo this week. The film explores the polarized debate on genetically-modified organisms (GMOs) and food, and how both pro- and anti-GMO camps claim science is on their side. The documentary, narrated by the accomplished astrophysicist Neil deGrasse Tyson, asks “How do we ensure that our food supply is safe, and that everyone has enough to eat? How do we feed the world while also protecting the planet? Has genetic engineering increased or decreased pesticide use? Are GMO foods bad for your health? And, most importantly, what data, evidence and sources are we using to approach these important questions?”

Ontario Genomics participated in the Toronto event, as did a strong showing of attendees on both sides of the debate. The film gives a thorough investigation into the many voices in this debate, with particular emphasis on the impact of the anti-GMO movement on areas of the world where food is not in abundance, where farmers want the choice to grow GMOs but are prevented from doing so by government-imposed bans influenced by a vocal anti-GMO movement. A surprising story to some was that of a genetically modified papaya developed in Hawaii that saved Hawaii’s papaya industry from ruin from a ringspot virus blight – and managed to avoid the state-wide ban on GMOs signed into law in 2013. And yet for others, GMOs are feared and avoided.

A Q&A session followed with the film’s director Scott Hamilton Kennedy, along with Carol T. Culhane, CEO of International Food Focus Ltd, Ian Affleck, Executive Director, Plant Biotechnology at CropLife Canada (Toronto), Greg Hannam, Ontario Grain Farmer (Woodrill Farms) and Motlatsi Musi, South African Farmer and author at Global Farmer Network; this was moderated by Kelly Hodgins, Program Coordinator, Feeding Nine Billion at the University of Guelph.

This Q&A session brought out the critical need for better communication – helping people understand and interpret scientific evidence, how to convey the risks and benefits of different approaches to feeding the world with the objective of building trust, how to have a better conversation between opposing sides.  It was clear from the discussion that the differences between the communities such as the organic vs. pro-GMO camps may not be as great as thought – safe, healthy food is the common driver.

South African farmer Motlatsi Musi is pro-GMO. He has been able to raise a family and send his son to university by farming with GMO corn. He is impatient now to receive GMO corn that can withstand drought, which is beginning to impact his corner of the world. He wants to have that choice.

Screenings of this film are planned across Canada. You can also arrange a local screening, or access the film through Amazon, iTunes, hulu, Google Play and YouTube.

Ontario-developed technology for screening variant libraries comes of age

Ranomics is a Toronto-based genomics company specializing in high-throughput mutagenesis and functional genomics screens, for the purpose of understanding genetic variations in human health. Leo Wan and Cathy Tie, who were both researchers at Mount Sinai Hospital at the time, founded the company in 2015. Both founders were distinguished scholars. Leo received his Ph.D. from the University of Toronto and was awarded the prestigious Vanier Canada Graduate Scholarship. Cathy is a Thiel Fellow and recent Forbes’ 30 under 30-award recipient. Soon after launching the company, Ranomics was accepted into the first cohort of Indie Bio and subsequently set up business operations at Johnson & Johnson Innovation, JLABS Toronto.

As part of their mission to understand the consequences of genetic variations in human health, Ranomics developed a propriety pipeline to create and characterize all possible variants of a human disease gene. This proprietary pipeline, which can be adapted for a wide range of other applications, is now available as part of Ranomics’ VariantFind™ platform. VariantFind™ provides ready to screen DNA variant libraries for any gene of interest, regardless of length, GC composition or complex sequences. The technology is more cost-effective compared to traditional gene synthesis with a faster turnaround time. VariantFind™ libraries seamlessly integrate into a wide selection of downstream workflows, including antibody optimization, drug target validation and enzyme, protein and organism engineering. Libraries are tailored specifically for partners and can include single site saturation libraries, combinatorial variant libraries or scanning mutagenesis libraries.

The OG business development team worked with Ranomics to identify new business vertical and market opportunities for their core DNA variant library building technology. The discussions led to the launch of VariantFind™, which has proven to be a highly valuable platform for the synthetic biology market. “With the help of OG business team, Ranomics has obtained 5x growth in revenue in the past 2 quarters” said Leo Wan, Chief Scientific Officer at Ranomics. With the assistance of the OG team, Ranomics continues to grow their VariantFind™ platform while continuing their on-going R&D programs in studying genetic variations in human health.

Find out more about Ranomics, or to arrange a meeting email the company at: info@ranomics.com. You can also see Ranomics present at the upcoming national synthetic biology event: “Engineering Biology for Solution in Health, Food and the Environment” on March 6, 2018.

Collaboration at heart and in practice

Ontario Genomics connects ideas, people, and organizations for collaborative investment opportunities in genomics-based applied research, translation and application.  Bringing people together to build and strengthen bridges across the ecosystem is in our DNA. We thank all of our colleagues, partners and stakeholders for participating and helping to make our recent Networking Event such a success.

OG Networking Event OG Networking Event OG Networking Event
OG Networking Event OG Networking Event OG Networking Event
OG Networking Event OG Networking Event OG Networking Event
OG Networking Event OG Networking Event OG Networking Event

Three Ontario projects awarded a total of $12.6M in funding

In a recent announcement from Genome Canada, three Ontario projects were awarded funding from Round 8 of the Genome Canada Genomics and Applied Partnership Program (GAPP). Ontario Genomics was pleased to work with the teams in putting together the proposals. GAPP funds translational research and development projects that address real-world challenges and opportunities as identified by industry, government, not-for-profits, and other “receptors” of genomics knowledge and technology. The three Ontario projects were:

1. Genomics Driven Engineering of Hosts for Bio-Nylon
Partners: BioAmber and Dr. Radhakrishnan Mahadevan of the University of Toronto
BioAmber, an industrial biotechnology company located in Sarnia, Ontario, has partnered with Dr. Radhakrishnan Mahadevan of the University of Toronto to make nylon derived from chemicals made from sugar, rather than from petroleum. Dr. Mahadevan has developed a genomics-driven bioengineering approach to convert sugars into value-added industrial chemicals such as adipic acid, used in producing nylon. This $5.7M project will help grow the biorefining industry and create new manufacturing jobs in Canada, while protecting the environment through reduced greenhouse gas emissions and pollution.

2. Validation of TAC receptors for use against liquid and solid tumours
Partners: Triumvira Immunologics and Dr. Jonathan Bramson, McMaster University
Canadian biotech company Triumvira Immunologics Inc., partnered with Jonathan Bramson of McMaster University, will use $2.3 million in funding to enhance Triumvira’s T-Cell Antigen Coupler (TAC) platform . This platform is used to create engineered T-cells for cancer treatment that are safer and equally or more efficacious than current engineered CAR (chimeric antigen receptor) T cells. Dr. Bramson will help validate TAC receptors carrying novel binding domains to expand the range of cancer targets TAC T-cells can attack. This will generate new treatment options for cancer patients.

3. Leveraging Leukocytes as Endogenous Biosensors to Create Novel Diagnostics for Preterm Birth
Partners: BGI Genomics and Dr. Stephen Lye, Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System
Approximately 2 million women are hospitalized annually in North America for Threatened Pre-Term Labour. But of these, only 20% will deliver preterm, exposing 80% to unnecessary interventions and hospitalization. Dr. Stephen Lye of the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, has identified blood-based markers that can predict which women, who experience too-early symptoms of labor, will go on to experience preterm birth of their infants. With $4.6M in funding, and as announced at the recent Ontario Premier’s mission to China, Dr. Lye will work with partner Xin Liu of BGI Genomics to develop these markers into a diagnostic test to improve maternal and newborn health.

Read about all Ontario GAPP projects

Producing a polyphenolics-enhanced Ice Syrup

Can we create a healthier Ice Syrup? Ontario Genomics is providing funding for an academic-industry partnership to do just that.

Sweet & Sticky Inc. located in the Niagara Peninsula produces Ice Syrup®, a unique non-alcoholic syrup made from Vidal and Cabernet Franc icewine grapes. Sweet and Sticky harvests their grapes in the coldest months of the year, when the content of desirable polyphenolics like resveratrol, pterostilbene, and dozens of others are peaking.  However, since Ice Syrup is non-alcoholic, only low concentrations of these desirable polyphenolics, which have low water solubility, make it into the final product. To address this limitation, Sweet & Sticky Inc. is collaborating with Prof. Jeff Stuart, from Brock’s Cool Climate Oenology and Viticulture Institute (CCOVI) 66-01-1_OGIto develop a ‘green extraction’ strategy for capturing the full spectrum of beneficial polyphenolics in Ice Syrup waste pomace and re-introducing it into the Ice Syrup product.  To realize this goal, the team, with the support of Ontario Genomics, is conducting full metabolomics profiling of their different extraction protocols to determine best practices. Having metabolomics data provides the necessary foundation for developing Sweet & Sticky’s strategies for production processes harvesting, post-harvest treatment, and extraction processes at an industrial scale. This will ensure best production and extraction conditions and the highest concentrations of the most relevant polyphenols in their new antioxidant enhanced Ice Syrup product.  This will also provide nutritional information that will be used for marketing purposes by Sweet & Sticky.